蛋白多肽類(lèi)藥物脂質(zhì)體是將蛋白多肽類(lèi)藥物用脂質(zhì)體包封后形成的載藥脂質(zhì)體，具有靶向、緩釋、良好的穩(wěn)定性等優(yōu)點(diǎn)。綜述了2000年以來(lái)中國(guó)專(zhuān)利申請(qǐng)中涉及的新型蛋白多肽類(lèi)藥物脂質(zhì)體，包括凝膠型脂質(zhì)體、前體脂質(zhì)體、長(zhǎng)循環(huán)脂質(zhì)體、免疫脂質(zhì)體、柔性脂質(zhì)體、pH敏感脂質(zhì)體、配體修飾脂質(zhì)體、磁性納米脂質(zhì)體、多囊脂質(zhì)體，為繼續(xù)開(kāi)發(fā)新型的蛋白多肽類(lèi)藥物脂質(zhì)體提供新的思路。

With the development of science and technology, electronic information technology has penetrated into many aspects of society now. Electronic informed consent is an effective way to adapt to development clinical trial. China is still at an early stage in this field. Affected by the outbreak of COVID-19 in 2020, the demand for electronic informed consent in clinical trial has become more urgent. Based on my own work experience, the author wants to analyze the problems in the traditional informed consent process and the current situations of electronic informed consent in China and explores the feasibility of electronic informed consent in clinical trials.